NCT06547203View on ClinicalTrials.gov

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 18, 2024

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2029

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Cetuximab

Cetuximab: 500 mg/m², intravenous infusion, once every 2 weeks

DRUG

Toripalimab

Toripalimab: 3 mg/kg, intravenous infusion, once every 2 weeks.

DRUG

Irinotecan

Irinotecan: 150 mg/m², intravenous infusion, once every 2 weeks.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER